Products for Research Use Only

Spironolactone-d3

CAT: 0804-HY-B0561S1Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0561S1Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Spironolactone-d3 is the deuterium labeled Spironolactone. Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC50 of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC50 of 77 nM. Spironolactone promotes autophagy in podocytes[1][2][3].
Product Name Alternative
SC9420-d3
UNSPSC
12352005
Target
Androgen Receptor; Autophagy; Isotope-Labeled Compounds; Mineralocorticoid Receptor
Type
Isotope-Labeled Compounds
Related Pathways
Autophagy; Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor
Field of Research
Metabolic Disease; Cancer
Purity
99.82
Solubility
DMSO : 50 mg/mL (ultrasonic; warming)
Smiles
C[C@@]12[C@@]3(OC(CC3)=O)CC[C@@]1([H])[C@@]4([H])[C@]([C@@]5(C(C[C@H]4SC(C([2H])([2H])[2H])=O)=CC(CC5)=O)C)([H])CC2
Molecular Formula
C24H29D3O4S
Molecular Weight
419.59
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Kim GK, et al. Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. J Clin Aesthet Dermatol. 2012;5 (3) :37-50.|[3]Fagart J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285 (39) :29932-29940.|[4]Dong D, et al. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes. Int Urol Nephrol. 2019;51 (4) :755-764.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products